Evidence map›Paper›PMID 38750137›Full record

ArticleLeukemia2024

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.

Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo Gambacorti-Passerini, Luca Mologni

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Diletta FontanaDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.ORCID 0000-0003-1633-6310
Federica MalighettiDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Matteo VillaDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.ORCID 0000-0002-6534-642X
Alfonso ZambonDepartment of Chemistry and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Carlo Gambacorti-PasseriniDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.ORCID 0000-0001-6058-515X
Luca MologniDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. luca.mologni@unimib.it.ORCID 0000-0002-6365-5149

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG-24828EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 675712
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug RepositioningDrug Resistance, NeoplasmFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID38750137
PMCPMC11286508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.